Polymorphisms in survivin (BIRC5 gene) are associated with age of onset in breast cancer patients

Sušac, Ilona; Ozretić, Petar; Gregorić, Maja; Levačić Cvok, Mirela; Sabol, Maja; Levanat, Sonja; Trnski, Diana; Eljuga, Domagoj; Seiwerth, Sven; Aralica, Gorana; Stanec, Mladen; Musani, Vesna (2019) Polymorphisms in survivin (BIRC5 gene) are associated with age of onset in breast cancer patients. Journal of Oncology, 2019 . ISSN 1687-8450

Preview

PDF - Published Version - article Available under License Creative Commons Attribution. Download (3MB) | Preview

Abstract

Survivin, encoded by BIRC5 gene (baculoviral IAP repeat containing 5), belongs to the family of inhibitors of apoptosis proteins (IAPs). In mammalian cells it participates in the control of mitosis, apoptosis regulation, and cellular stress response. Its expression is increased in almost all types of cancers. The aim of this study was to investigate the role of BIRC5 polymorphisms in breast cancer (BC) and to connect survivin expression with various clinicopathological characteristics of BC patients. Blood and archival tumour tissue samples were collected from 26 BC patients from Croatia. Survivin expression was determined immunohistochemically. BIRC5 promoter, coding region, and 3’UTR were genotyped. DNA from 74 healthy women was used as control. BIRC5 polymorphisms and survivin expression were tested against age of onset, histological grade, tumour type and size, lymph node status, oestrogen, progesterone, Her2, and Ki67 status. Numbers of samples with weak, moderate, and strong survivin expression were 9 (33.3%), 11 (40.7%), and 7 (25.9%), respectively. Most patients had nuclear survivin staining (92.6%). High survivin expression was significantly associated with negative oestrogen receptor status (p=0.007) and positive Ki67 expression (p=0.032). Ki67 expression was also positively correlated with histological grade (p=0.0009). Fourteen polymorphisms were found in BC samples, located mostly in promoter and 3’UTR of BIRC5. There was no significant difference in the distribution of polymorphisms between BC and control samples. Among clinicopathological characteristics of BC patients, alleles of five BIRC5 polymorphisms were associated with younger age of onset: c.-644T>C (55.8 years [y] vs. 48.1 y ; p=0.006), c.-241C>T (54.2 y vs. 45.0 ; p=0.029), c.9809T>C (55.8 y vs. 48.1 y ; p=0.006), c.-1547C>T (58.3 y vs. 50.9 y ; p=0.011), and c.9386T>C (50.8 y vs. 59.5 y ; p=0.004). To assess the significance of BIRC5 polymorphisms and survivin expression as predictive and prognostic biomarkers for BC further research with a larger sample size is needed.

Item Type:	Article
Uncontrolled Keywords:	BIRC5 ; survivin ; polymorphisms ; breast cancer ; IHC
Subjects:	NATURAL SCIENCES > Biology BIOMEDICINE AND HEALTHCARE > Basic Medical Sciences BIOMEDICINE AND HEALTHCARE > Clinical Medical Sciences
Divisions:	Division of Molecular Medicine
Depositing User:	Dr.sc. Petar Ozretić
Date Deposited:	02 Aug 2019 12:01
URI:	http://fulir.irb.hr/id/eprint/4939
DOI:	10.1155/2019/3483192

Actions (login required)

View Item